Compugen (CGEN) Competitors $1.41 -0.01 (-0.70%) Closing price 04:00 PM EasternExtended Trading$1.40 -0.01 (-0.71%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGEN vs. ALMS, ARCT, EOLS, BCYC, TECX, NBTX, CGEM, MBX, PRME, and PRTAShould you be buying Compugen stock or one of its competitors? The main competitors of Compugen include Alumis (ALMS), Arcturus Therapeutics (ARCT), Evolus (EOLS), Bicycle Therapeutics (BCYC), Tectonic Therapeutic (TECX), Nanobiotix (NBTX), Cullinan Therapeutics (CGEM), MBX Biosciences (MBX), Prime Medicine (PRME), and Prothena (PRTA). These companies are all part of the "pharmaceutical products" industry. Compugen vs. Its Competitors Alumis Arcturus Therapeutics Evolus Bicycle Therapeutics Tectonic Therapeutic Nanobiotix Cullinan Therapeutics MBX Biosciences Prime Medicine Prothena Compugen (NASDAQ:CGEN) and Alumis (NASDAQ:ALMS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation. Which has more volatility & risk, CGEN or ALMS? Compugen has a beta of 2.58, indicating that its share price is 158% more volatile than the S&P 500. Comparatively, Alumis has a beta of -1.38, indicating that its share price is 238% less volatile than the S&P 500. Which has preferable earnings and valuation, CGEN or ALMS? Compugen has higher revenue and earnings than Alumis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompugen$27.86M4.52-$14.23M-$0.22-6.41AlumisN/AN/A-$294.23MN/AN/A Do analysts recommend CGEN or ALMS? Compugen currently has a consensus target price of $4.00, suggesting a potential upside of 183.69%. Alumis has a consensus target price of $20.17, suggesting a potential upside of 338.41%. Given Alumis' stronger consensus rating and higher possible upside, analysts clearly believe Alumis is more favorable than Compugen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compugen 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Alumis 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the media prefer CGEN or ALMS? In the previous week, Alumis had 1 more articles in the media than Compugen. MarketBeat recorded 2 mentions for Alumis and 1 mentions for Compugen. Alumis' average media sentiment score of 0.38 beat Compugen's score of 0.25 indicating that Alumis is being referred to more favorably in the news media. Company Overall Sentiment Compugen Neutral Alumis Neutral Is CGEN or ALMS more profitable? Alumis has a net margin of 0.00% compared to Compugen's net margin of -87.45%. Compugen's return on equity of -34.77% beat Alumis' return on equity.Company Net Margins Return on Equity Return on Assets Compugen-87.45% -34.77% -16.82% Alumis N/A -119.15%-92.50% Do institutionals & insiders have more ownership in CGEN or ALMS? 12.2% of Compugen shares are owned by institutional investors. 9.5% of Compugen shares are owned by company insiders. Comparatively, 40.7% of Alumis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryAlumis beats Compugen on 8 of the 14 factors compared between the two stocks. Get Compugen News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGEN vs. The Competition Export to ExcelMetricCompugenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$126.72M$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.71%4.51%P/E Ratio-6.417.5859.1122.53Price / Sales4.52458.96547.00119.09Price / CashN/A44.5237.0558.92Price / Book2.279.9310.916.06Net Income-$14.23M-$53.38M$3.29B$266.28M7 Day Performance0.71%0.05%0.01%-0.76%1 Month Performance-3.42%7.08%7.06%3.83%1 Year Performance-28.43%11.92%50.09%24.39% Compugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGENCompugen2.3774 of 5 stars$1.41-0.7%$4.00+183.7%-26.0%$126.72M$27.86M-6.4170Positive NewsShort Interest ↓ALMSAlumis2.5714 of 5 stars$4.90+1.2%$20.17+311.6%-61.6%$503.67MN/A0.00N/AARCTArcturus Therapeutics3.6569 of 5 stars$17.71-4.3%$50.57+185.6%-11.3%$502.63M$152.31M-7.94180News CoverageAnalyst ForecastEOLSEvolus4.5294 of 5 stars$7.43-3.3%$21.25+186.0%-52.6%$496.78M$266.27M-7.58170News CoveragePositive NewsShort Interest ↓BCYCBicycle Therapeutics3.364 of 5 stars$7.12+0.3%$22.22+212.1%-65.9%$491.70M$35.28M-2.03240Positive NewsTECXTectonic Therapeutic2.7759 of 5 stars$24.57-6.1%$80.33+227.0%-14.9%$489.88MN/A-6.08120News CoveragePositive NewsAnalyst ForecastNBTXNanobiotix0.4286 of 5 stars$9.85-2.4%$8.00-18.8%+64.0%$483.95M$39.18M0.00100Gap DownCGEMCullinan Therapeutics2.6849 of 5 stars$7.64-6.7%$26.80+250.8%-58.3%$483.82MN/A-2.3730Positive NewsMBXMBX BiosciencesN/A$13.89-3.1%N/AN/A$481.40MN/A-3.06N/ANews CoveragePRMEPrime Medicine3.535 of 5 stars$3.52-0.8%$8.92+153.3%-13.5%$473.70M$4.96M-1.72234Positive NewsPRTAProthena3.3413 of 5 stars$8.38-4.4%$30.25+261.0%-60.5%$472.09M$135.16M-1.49130News CoverageAnalyst Forecast Related Companies and Tools Related Companies Alumis Alternatives Arcturus Therapeutics Alternatives Evolus Alternatives Bicycle Therapeutics Alternatives Tectonic Therapeutic Alternatives Nanobiotix Alternatives Cullinan Therapeutics Alternatives MBX Biosciences Alternatives Prime Medicine Alternatives Prothena Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGEN) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
